Yilmaz Melek Tugce, Hurmuz Pervin, Dag Osman, Yigit Ecem, Ozyurek Yasin, Avci Hanife, Cengiz Mustafa
Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Department of Biostatistics, Hacettepe University, Ankara, Turkey.
J Gastrointest Cancer. 2025 Jan 11;56(1):39. doi: 10.1007/s12029-025-01167-2.
The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.
We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method. Prognostic factors were identified through univariate and multivariate Cox regression analyses. A nomogram was constructed based on significant predictive factors for OS, including lymph node ratio, T classification, tumor location, and local recurrence.
The median follow-up duration was 41.5 months (range, 6-144.8 months). The 2- and 5-year OS and progression-free survival were 77% and 53% and 64% and 49%, respectively. In multivariate analysis, tumor location (distal vs. proximal), pT classification (pT1-2 vs. pT3-4), lymph node ratio (< 0.18 vs. ≥ 0.18), and presence of local recurrence were independent prognostic factors for OS. The optimal cut-off value for the total nomogram score predicting OS was 116 points. Patients with < 116 points had 2- and 5-year OS rates of 87% and 73%, respectively, compared to 67% and 30% for those with ≥ 116 points.
A nomogram was constructed incorporating lymph node ratio, T classification, tumor site, and local recurrence for gastric cancer patients receiving adjuvant CRT. Patients with a total score below 116 demonstrated higher survival rates. This nomogram may aid in defining optimal follow-up intervals.
本研究旨在确定影响接受辅助放化疗(CRT)的胃癌患者总生存期(OS)的预后因素,并建立一个预测模型。
我们回顾性评估了2010年至2020年期间接受辅助CRT或放疗的245例非转移性胃癌患者。采用Kaplan-Meier法进行生存分析。通过单因素和多因素Cox回归分析确定预后因素。基于OS的显著预测因素构建了列线图,这些因素包括淋巴结比率、T分期、肿瘤位置和局部复发。
中位随访时间为41.5个月(范围6 - 144.8个月)。2年和5年的总生存期及无进展生存期分别为77%和53%以及64%和49%。在多因素分析中,肿瘤位置(远端与近端)、pT分期(pT1 - 2与pT3 - 4)、淋巴结比率(<0.18与≥0.18)以及局部复发的存在是OS的独立预后因素。预测OS的总列线图评分的最佳临界值为116分。评分<116分的患者2年和5年总生存率分别为87%和73%,而评分≥116分的患者分别为67%和30%。
为接受辅助CRT的胃癌患者构建了一个包含淋巴结比率、T分期、肿瘤部位和局部复发的列线图。总分低于116分的患者生存率更高。该列线图可能有助于确定最佳随访间隔。